Market data not licensed for redistribution.
Pharos iBio
388870 ยท KOSDAQ ยท R&D in Natural Sciences & Engineering
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)โ
PERโ
PBRโ
ROE %-97.7
Debt ratio % (liabilities / equity)170
Revenue TTM (KRW bn)โ
Op. profit TTM (KRW bn)-10.6
Dividend yield %โ
Basis: market cap at โฆ; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
| 2026-12-19 | Convertible bonds (CB): conversion / exercise period starts โ 14.11% of shares ยท price โฉ8,935 ยท refix floor โฉ8,000 (89.5%) ยท size โฉ19.0bn | High |
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | โ | โ | 0.0 | โ | โ |
| Operating profit | โ | โ | -10.1 | -12.6 | -11.5 |
| Net income | โ | โ | -8.9 | -10.6 | -10.8 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | 0.0 | โ | โ | โ | โ | โ |
| Operating profit | -3.1 | -2.4 | -3.0 | -2.9 | -2.4 | -2.3 |
| Net income | -3.0 | -2.8 | -1.8 | -3.1 | -2.2 | -2.3 |
Largest shareholder
As of the 2025 annual report: ์ค์ ํ and related parties hold 32.95% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-08-13 | Periodic report (annual/half/quarterly) ๋ฐ๊ธฐ๋ณด๊ณ ์ (2026.06) | DART original | |
| 2026-07-20 | CB conversion / price adjustment ์ ํ๊ฐ์ก์์กฐ์ (์ 1ํ์ฐจ) | DART original | |
| 2026-06-04 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-06-01 | Other material event (investment-relevant) ๊ธฐํ๊ฒฝ์์ฌํญ(์์จ๊ณต์) ([๊ตญ์ฑ ๊ณผ์ ์ ์ ] ๋ณด๊ฑด๋ณต์ง๋ถ ์ฃผ๊ด 2026๋ ๋ ๊ตฌ์กฐ๊ธฐ๋ฐ AI ์ ์ฝ๊ฐ๋ฐ์ง์ ์ฌ์ ํ์ฝ ์ฒด๊ฒฐ) | DART original | |
| 2026-05-14 | Periodic report (annual/half/quarterly) ๋ถ๊ธฐ๋ณด๊ณ ์ (2026.03) | DART original | |
| 2026-04-13 | IR event ๊ธฐ์ ์ค๋ช ํ(IR)๊ฐ์ต | DART original | |
| 2026-03-27 | Governance / misc. (routine) ๋ณธ์ ์์ฌ์ง๋ณ๊ฒฝ | DART original | |
| 2026-03-27 | Shareholder meeting ์ ๊ธฐ์ฃผ์ฃผ์ดํ๊ฒฐ๊ณผ | DART original | |
| 2026-03-27 | Governance / misc. (routine) ๋ ๋ฆฝ์ด์ฌ์์ ์ใํด์๋๋์ค๋ํด์์๊ดํ์ ๊ณ | DART original | |
| 2026-03-19 | Periodic report (annual/half/quarterly) ์ฌ์ ๋ณด๊ณ ์ (2025.12) | DART original | |
| 2026-03-18 | Audit report submission ๊ฐ์ฌ๋ณด๊ณ ์์ ์ถ | DART original | |
| 2026-03-11 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ณต๊ณ | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-06-01 | Other material event (investment-relevant) | +2.1% | -1.4% | -2.8% |
| 2025-12-03 | Convertible bond issuance | -1.7% | +18.5% | +19.7% |
| 2025-06-30 | Clinical trial / regulatory approval | +5.9% | -4.9% | -12.0% |
| 2025-06-25 | Clinical trial / regulatory approval | +13.1% | -7.6% | -13.5% |
| 2025-03-05 | Clinical trial / regulatory approval | -0.4% | -1.1% | -11.3% |
| 2024-02-14 | Revenue/profit change >=30% (15% large caps) | +0.4% | +0.3% | +19.6% |
| 2023-12-18 | Other material event (investment-relevant) | +7.1% | +4.4% | +17.0% |
| 2023-10-30 | Acquisition of shares in another company | +3.7% | -4.7% | +7.1% |
| 2023-10-10 | Other material event (investment-relevant) | +0.4% | -0.0% | -12.1% |
| 2023-09-12 | Other material event (investment-relevant) | -12.6% | -4.1% | -30.2% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer โ Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view